Cargando…

Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer

BACKGROUND: Previous clinical data have shown that raltegravir-based antiretroviral therapy (ART) with fewer drug-drug interactions (DDIs) and adverse events (AEs) is a good regimen in patients with HIV infection who need cancer chemotherapy. There are currently few data on ART regimens that include...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jing, Wei, Guo, Gui, Fuqiang, Zhao, Yong, Chen, Tingyu, Tan, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508721/
https://www.ncbi.nlm.nih.gov/pubmed/36151562
http://dx.doi.org/10.1186/s12981-022-00470-3
_version_ 1784797077792882688
author Yang, Jing
Wei, Guo
Gui, Fuqiang
Zhao, Yong
Chen, Tingyu
Tan, Juan
author_facet Yang, Jing
Wei, Guo
Gui, Fuqiang
Zhao, Yong
Chen, Tingyu
Tan, Juan
author_sort Yang, Jing
collection PubMed
description BACKGROUND: Previous clinical data have shown that raltegravir-based antiretroviral therapy (ART) with fewer drug-drug interactions (DDIs) and adverse events (AEs) is a good regimen in patients with HIV infection who need cancer chemotherapy. There are currently few data on ART regimens that include Integrase inhibitors (INSTIs) other than RAL among this patient subgroup. METHODS: We evaluated the safety and efficacy of different kinds of INSTI-based regimens among patients with HIV and concomitant colorectal cancer (CRC) who received antineoplastic agents. RESULTS: From January 2020 to November 2021, 66 patients were enrolled. The patients were divided into three groups: 20 patients treated with dolutegravir (DTG)/lamivudine (3TC)/tenofovir (TDF) (group I), 24 patients treated with DTG/albuvirtide (ABT) (group II), and 22 patients treated with bictegravir (BIC)/tenofovir alafenamide (TAF)/emtricitabine (FTC) (group III). The majority of AEs during treatment were of grade 1–2. Treatment‐related AEs of grade 3–4 occurred in 6 patients (9.09%), and no grade 5 AEs occurred. The most common AEs were nausea (100%) and neutrophils (84.85%) attributed to anticancer agents, and there was no significant difference in the incidence of these AEs among the three groups (P > 0.05). Viral load rebound was not observed among pretreated patients during chemotherapy. The viral load of untreated patients who started their ART concomitant with chemotherapy almost decreased to the lower limit of detection 6 months after ART initiation (only one patient in group III had a viral load of 102 copies/ml). At the 6th month, the CD4 count in group I decreased significantly from baseline (P < 0.05). However, the change in CD4 count was not significant in group II (P = 0.457) or group III (P = 0.748). CONCLUSIONS: DTG- or BIC-containing regimens are good options for patients with HIV and concomitant CRC.
format Online
Article
Text
id pubmed-9508721
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-95087212022-09-25 Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer Yang, Jing Wei, Guo Gui, Fuqiang Zhao, Yong Chen, Tingyu Tan, Juan AIDS Res Ther Research BACKGROUND: Previous clinical data have shown that raltegravir-based antiretroviral therapy (ART) with fewer drug-drug interactions (DDIs) and adverse events (AEs) is a good regimen in patients with HIV infection who need cancer chemotherapy. There are currently few data on ART regimens that include Integrase inhibitors (INSTIs) other than RAL among this patient subgroup. METHODS: We evaluated the safety and efficacy of different kinds of INSTI-based regimens among patients with HIV and concomitant colorectal cancer (CRC) who received antineoplastic agents. RESULTS: From January 2020 to November 2021, 66 patients were enrolled. The patients were divided into three groups: 20 patients treated with dolutegravir (DTG)/lamivudine (3TC)/tenofovir (TDF) (group I), 24 patients treated with DTG/albuvirtide (ABT) (group II), and 22 patients treated with bictegravir (BIC)/tenofovir alafenamide (TAF)/emtricitabine (FTC) (group III). The majority of AEs during treatment were of grade 1–2. Treatment‐related AEs of grade 3–4 occurred in 6 patients (9.09%), and no grade 5 AEs occurred. The most common AEs were nausea (100%) and neutrophils (84.85%) attributed to anticancer agents, and there was no significant difference in the incidence of these AEs among the three groups (P > 0.05). Viral load rebound was not observed among pretreated patients during chemotherapy. The viral load of untreated patients who started their ART concomitant with chemotherapy almost decreased to the lower limit of detection 6 months after ART initiation (only one patient in group III had a viral load of 102 copies/ml). At the 6th month, the CD4 count in group I decreased significantly from baseline (P < 0.05). However, the change in CD4 count was not significant in group II (P = 0.457) or group III (P = 0.748). CONCLUSIONS: DTG- or BIC-containing regimens are good options for patients with HIV and concomitant CRC. BioMed Central 2022-09-23 /pmc/articles/PMC9508721/ /pubmed/36151562 http://dx.doi.org/10.1186/s12981-022-00470-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yang, Jing
Wei, Guo
Gui, Fuqiang
Zhao, Yong
Chen, Tingyu
Tan, Juan
Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer
title Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer
title_full Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer
title_fullStr Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer
title_full_unstemmed Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer
title_short Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer
title_sort safety and efficacy of pharmacotherapy containing instis and chemotherapy drugs in people living with hiv and concomitant colorectal cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508721/
https://www.ncbi.nlm.nih.gov/pubmed/36151562
http://dx.doi.org/10.1186/s12981-022-00470-3
work_keys_str_mv AT yangjing safetyandefficacyofpharmacotherapycontaininginstisandchemotherapydrugsinpeoplelivingwithhivandconcomitantcolorectalcancer
AT weiguo safetyandefficacyofpharmacotherapycontaininginstisandchemotherapydrugsinpeoplelivingwithhivandconcomitantcolorectalcancer
AT guifuqiang safetyandefficacyofpharmacotherapycontaininginstisandchemotherapydrugsinpeoplelivingwithhivandconcomitantcolorectalcancer
AT zhaoyong safetyandefficacyofpharmacotherapycontaininginstisandchemotherapydrugsinpeoplelivingwithhivandconcomitantcolorectalcancer
AT chentingyu safetyandefficacyofpharmacotherapycontaininginstisandchemotherapydrugsinpeoplelivingwithhivandconcomitantcolorectalcancer
AT tanjuan safetyandefficacyofpharmacotherapycontaininginstisandchemotherapydrugsinpeoplelivingwithhivandconcomitantcolorectalcancer